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Enterococcus faecium SF68® (SF68) is a licensed pharmaceutical for treatment and
prevention of diarrhea in Austria, Italy and Switzerland. However, as for other probiotics,
evidence for its efficacy is based on small to medium-sized studies. Four unpublished
studies on the treatment of acute diarrhea and the prevention of antibiotic-associated
diarrhea were analyzed: one randomized, double blind, placebo-controlled trial (RCT)
for treatment (n = 1,143), one open-label study for treatment (n = 5,093), one RCT for
prevention (n = 1,397) and one open-label study for prevention (n = 4,340). Patients
in the treatment-arm and the open-label studies received SF68 (b.i.d. for the prevention
studies, t.i.d. for the treatment trials) for 7 days. Primary end points were time to resolution
of diarrhea (treatment) and percentage of development of diarrhea (prevention). The
primary endpoint of the treatment study was met with a decreased time to resolution of
diarrhea in SF68-treated patients compared to controls (median 3 vs. 4 days, p< 0.001).
Time to resolution of secondary symptoms was also significantly reduced. Preventive
treatment with SF68 was more effective than placebo with development of diarrhea in
8.6 vs. 16.2% (p < 0.001). Results from the open-label studies were consistent with
the RCTs. The incidence of adverse events were low (1.1 and 1.4% in the RCT and 4.7
and 7.4% in the open-label studies). SF68 is effective and safe in the treatment of acute
diarrhea and prevention of antibiotic-associated diarrhea.
Keywords: acute diarrhea, treatment, prevention, randomized-controlled trial, probiotics, Enterococcus faecium,
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INTRODUCTION
Acute diarrhea is a frequent problem in an outpatient setting (1). Despite its mostly self-limiting
disease course, acute diarrhea considerably affects morbidity and mortality (2). High mortality due
to gastrointestinal infections is particularly seen in under-developed countries (3). Acute diarrhea
further results in high direct and indirect health-care costs (4, 5). Except for some bacterial causes,
no effective treatment exists, and current therapeutic strategies are mainly supportive.
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Probiotics are increasingly used for both treatment of acute
diarrhea and prevention of antibiotic-associated diarrhea, more
so in children than adults. Most of to-date available data
have emerged from clinical trials with Lactobacillus rhamnosus
GG and Saccharomyces boulardii (6, 7). Current pediatric
guidelines strongly recommend their therapeutic use as add-
on to rehydration despite a low quality of evidence (8). So far
conducted trials lack consistency, in some cases studies were
neither blinded nor placebo controlled. Moreover, almost all of
them consisted of small to moderate sample sizes. The evidence
supporting the use of other probiotics such as Lactobacillus
reuteri is even weaker (9, 10). Findings from trials with one
probiotic cannot be extrapolated to another probiotic compound
since different bacterial strains might have various effects.
Therefore, no generalizable class statement can be made.
Enterococcus faecium SF68 R© (SF68) is a licensed
pharmaceutical in Austria, Italy and Switzerland. Its indications
are (i) treatment of acute infectious enteritis in children and
adults; (ii) traveler‘s diarrhea; and (iii) prevention and treatment
of antibiotic-associated diarrhea. In a comprehensive Cochrane
Review on the treatment of acute infectious diarrhea with
probiotics, four randomized controlled trials (RCT, n = 333)
that evaluated SF68 qualified for inclusion demonstrating
reduced risk for diarrhea lasting 4 days or longer (11). However,
quality of the trials conducted with SF68 was insufficient with
unclear or inadequate allocation concealment, no blinding in
some trials and no or unclear intention to treat analyses (9).
In addition, several trials published were not included in the
analysis (12–16). There are no known side-effects to SF68,
but due to the existence of vancomycin resistant Enterococci
and the risk of its transmission, the safety of this genus has
been questioned for a long time (17). Therefore, its use is
currently not recommended by the European Society for
Pediatric Gastroenterology, Hepatology and Nutrition (9).
However, safety should be assessed at strain level and the safety
of SF68 including absence of vancomycin resistance issues has
been extensively documented and recently summarized in a
comprehensive review (18).
Here, we report on two randomized-controlled, double blind
trials and two open-label studies for the treatment of acute
diarrhea and prevention of antibiotic-associated diarrhea with
Enteroccus faecium SF68 R© in juvenile and adult patients, which
have included a total of 11,973 patients.
MATERIALS AND METHODS
Study Design
This was an analysis of two RCTs and two open-label
studies for the treatment of acute diarrhea and prevention of
antibiotic-associated diarrhea. All four studies were designed
and completed prior to the publication of the European Good-
Clinical-Practice (GCP) guidelines in 1989 and before an
institutional review board was established at the institution
of the primary investigator, the late Professor Mauro Moroni
(University of Milan, Italy). However, the studies adhered to
the rules and regulations applicable in Italy at that time.
This manuscript is based on the study report and a detailed
statistical analysis prepared by Gipharmex (Milan, Italy), which
had been submitted to regulatory authorities in applicable
countries and reported as a supplement in an educational
magazine owned by Gipharmex (Kole: Continuing Education in
Gastroenterology, Supplementary Datasheet 1). Sanofi-Aventis
holds the marketing authorization for SF68 as well as the
rights regarding use, publication of the findings from this study
report. Raw data were not accessible since obligation to preserve
records has been time-barred in the meantime. A summary
of the data was presented at the 1986 World Congress of
Gastroenterology (19).
Patients and Data Collection
Subjects were recruited in the early 1980s at 150 hospitals and 653
outpatient general practitioner offices, all located in Italy. Patients
recruited in the hospitals could be inpatients or outpatients.
For the treatment studies, the following inclusion criteria were
applied: (i) adult or school-aged patients suffering from acute
diarrhea without detectable signs of sepsis and/or involvement
of other organs. Patients were excluded for: (i) history of food
intolerance; and (ii) infectious diarrheas caused by Salmonella,
Entamoeba, Giardia or other parasites. Patients were seen at
baseline and had daily follow-up for a total of 7 days. The
following items were documented: number of stools, consistency
of stools, mucus in stool, abdominal pain, bloating, nausea,
vomiting, fever, and adverse events. Further items on the case
record forms at baseline included demographic parameters,
assumed cause of diarrhea, treatment setting (inpatient vs.
outpatient). In case of early discontinuation of treatment, reasons
(early cure, adverse events, unrelated to treatment and disease)
were documented.
For the prevention studies, inclusion criteria were: (i)
adults or school-age patients receiving oral or intravenous
antibiotic treatment. Patients were excluded for treatment
with tetracyclines. Patients were seen at baseline and daily
for the next 7 days. The following data were collected at
baseline: demographic parameters, treatment setting (inpatient
vs. outpatient), type of underlying infection (respiratory,
urological, other), type of antibiotic. If diarrhea occurred, the
following data were collected: (i) first day of diarrhea; (ii) severity
graded into mild (up to 2–3 liquid or semiliquid stools without
mucus/blood), moderate (4–6 mostly liquid stools, or stools with
mucus), and severe (more than six liquid stools, mostly with
mucus, sometimes with blood); (iii) duration of diarrhea; and (iv)
presence of glossitis, labial and anal fissures. The study flow chart
(RCT) is illustrated in Figure 1.
Randomization and Treatment
Patients in the RCTs were randomized 1:1 into the
treatment/prevention group or the placebo group. Subjects
randomized into the interventional groups and patients in the
open-label study received one capsule of SF68 (containing at
least 75 million cells in dehydrated form) three times a day
(treatment studies) and twice daily (prevention studies) for an
intended duration of seven days.
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FIGURE 1 | Study flow chart in the two randomized controlled trials.
Measurements
The following primary endpoints were defined:
- Treatment studies: Time to resolution of diarrhea (defined as
≥3 stools per day or liquid or semiliquid stools)
- Prevention studies: Percent of patients developing antibiotic-
associated diarrhea
Secondary endpoints for the treatment studies were duration of
presence of (i) ≥3 stools, (ii) liquid or semiliquid stools, (iii)
mucus on stool, and (iv) abdominal pain.
Secondary endpoints for the prevention studies were severity
and duration of diarrhea, and occurrence of glossitis, labial and
anal fissures.
Study Power and Statistical Analysis
Retrospective power analysis based on an estimated median
duration of acute diarrhea of 4 days yielded a sample size of 774
to be sufficient to detect a 20% relative reduction in the rate of
patients with ongoing diarrhea at day 4 (from 50 to 40%) with a
power of 80% (treatment study). A sample size of 1,228 patients
was determined to detect a 30% relative reduction in the rate of
new-onset diarrhea (based on an estimated incidence of 20%)
with a power of 80% (prevention study). Effect sizes were chosen
based on previous publications (20).
Original data had been analyzed by the Biometric andMedical
Statistic Unit of Gipharmex using the statistical programs
Framework (Ashton-Tate, Torrance, CA, USA) and SL-Micro
software (Questionnaire Service Company, East Lansing, MI,
USA). Independent statistical re-analyses based on the study
report provided by Gipharmex were performed by the authors
using Prism version 7.1 (Graphpad Software, La Jolla, CA,
USA). Categorical data are summarized as the percentage of
the group total. Comparison between categorical data was
performed using χ2 test. For calculation of percentage of patients
with ongoing diarrhea over time, Kaplan Meier curves were
computed. Kaplan Meier curves were compared using log-rank




One thousand one hundred thirty-four patients were randomized
1:1 into the control (570 patients) and SF68 group (564 patients).
Baseline demographics and disease characteristics were similar in
the two groups (Table 1). All subjects were enrolled by hospital-
based physicians, however 19.5% of patients had outpatient
follow-up visits. 458 (placebo group) and 458 patients (SF68 arm)
completed the seven-day treatment course (Figure 1).
Primary outcome was met with a significantly shorter time
until resolution of diarrhea in the treatment compared to the
control group (median 3 vs. 4 days, log-rank test p < 0.001)
with a hazard ratio of 0.7363 (confidence interval 0.6491–
0.8353) for resolution of diarrhea (=dependent variable). The
corresponding Kaplan Meier curves are shown in Figure 2. At
day 3 of treatment, significantly fewer patients in the SF68 group
(50.2%) reported ongoing diarrhea compared to controls (59.2%,
p= 0.002, intention-to-treat analysis).
Time to resolution of other symptoms (≥3 stools per day,
presence of liquid or semi-liquid stools, mucus on stools, and
abdominal pain) was also significantly reduced in the SF68 group
compared to controls (Figure 3).
Open-Label Treatment Study
Five thousand ninety-three outpatient subjects were enrolled
in the open-label treatment study. Compared to the RCT,
included patients were younger and more frequently reported
food-borne illness and traveler‘s diarrhea as possible underlying
cause. Disease severity at baseline was comparable to the
RCT. However, abdominal pain and bloating were more
frequently reported (Table 1). Primary and secondary outcomes
were comparable to those seen in the RCT treatment group
(Supplementary Figure 2).
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TABLE 1 | Baseline demographics and disease characteristics for the treatment studies.
Randomized Open-label
Placebo SF68 total
Gender Male 296 (51.9) 286 (50.7) 582 (51.3) 25,82 (50.7)
Female 274 (48.1) 278 (49.3) 552 (48.7) 2,511 (49.3)
Age <14 years 44 (7.7) 43 (7.6) 87 (7.7) 622 (12.2)
14–20 years 18 (3.2) 13 (2.3) 31 (2.7) 438 (8.6)
21–40 years 86 (15.1) 115 (20.4) 201 (17.7) 1,711 (33.6)
41–60 years 154 (27.0) 141 (25.0) 295 (26.0) 1,441 (28.3)
61–70 years 101 (17.7) 111 (19.7) 212 (18.7) 474 (9.3)
>70 years 167 (29.3) 141 (25.0) 308 (27.2) 407 (8.0)
Treatment setting Hospital 466 (81.8) 447 (79.3) 913 (80.5) -
Outpatient 104 (18.2) 117 (20.7) 221 (19.5) 5,093 (100.0)
Cause Food 105 (18.4) 111 (19.7) 216 (19.0) 1,838 (36.1)
Infection 103 (18.1) 82 (14.5) 185 (16.3) 922 (18.1)
Iatrogenic 85 (14.9) 87 (15.4) 172 (15.2) 504 (9.9)
Toxic 60 (10.5) 51 (9.0) 111 (9.8) 652 (12.8)
Travel 14 (2.5) 16 (2.8) 30 (2.6) 484 (9.5)
Unknown 203 (35.6) 217 (38.5) 420 (37.0) 693 (13.6)
Number of stools per day 3 128 (22.5) 130 (23.0) 258 (22.8) 1,181 (23.2)
4 143 (25.1) 147 (26.1) 290 (25.6) 1,294 (15.4)
5 90 (15.8) 87 (15.4) 177 (15.6) 1,069 (21.0)
6 72 (12.6) 73 (12.9) 145 (12.8) 637 (12.5)
>6 137 (24.0) 127 (22.5) 264 (23.3) 912 (17.9)
Stool consistency Liquid 394 (69.1) 399 (70.7) 793 (69.9) 3,448 (67.7)
Semi-liquid 176 (30.9) 165 (29.3) 341 (30.1) 1,645 (32.3)
Other signs/symptoms Mucus on feces 220 (38.6) 205 (36.3) 425 (37.5) 2,052 (40.3)
Abdominal pain 387 (67.9) 386 (68.4) 773 (62.2) 4,074 (80.0)
Meteorism 334 (58.6) 360 (63.8) 694 (61.2) 3,351 (65.8)
Nausea 241 (42.3) 246 (43.6) 487 (42.9) 2,124 (41.7)
Vomiting 156 (27.4) 167 (29.6) 323 (28.5) 1,401 (27.5)
Fever 220 (38.6) 197 (34.9) 417 (36.8) 1,625 (31.9)
Data are shown as number of patients and % of group in parentheses.
Randomized Prevention Study
One thousand three hundred ninety-seven patients were
randomized 1:1 into the control group (700 subjects) and
the SF68 arm (697 subjects). Baseline demographics and
disease characteristics were comparable between the two
groups (Table 2). All patients were enrolled by hospital-
based physicians, 9.1% of patients were subsequently followed
as outpatients. Patients were mainly treated for respiratory
and urogenital infections (61.0 and 17.8%, respectively). The
most commonly prescribed antibiotics were: cephalosporins
(35.4%), ampicillin/amoxicillin (26.1%), and aminoglycosides
(11.3%). In more than two thirds, antibiotics were administered
intravenously. 662 (placebo group) and 661 patients (SF68 arm)
completed the seven-day treatment course (Figure 1).
The primary endpoint was met with significantly fewer
patients developing diarrhea in the SF68 arm (8.6%) compared
to the control group (16.2%, p < 0.001, Table 3, per protocol
analysis). In the intention-to-treat analysis, these rates were 8.2
vs. 15.3% (p < 0.001). In patients developing diarrhea, longer
lasting diarrhea (≥2 days) was less frequently observed in the
SF68 vs. control group (68.4 vs. 86%, p = 0.008). However, there
were no significant differences regarding severity and time to
onset of diarrhea between the two groups (Table 3).
Open-Label Prevention Study
Four thousand six hundred sixty-four outpatient subjects were
enrolled in the open-label prevention study. As compared
to the RCT, included patients were younger and more
frequently reported urological infections as underlying disease.
Cotrimoxazole, erythromycin and clindamycin were more
often used, while use of cephalosporins and aminoglycosides
was less frequent, mostly due to fewer intravenous
regimens (Table 2).
Diarrhea occurred in 11.5% of patients, which was mostly
of light severity and short duration. The incidence was higher
compared to SF68 arm in the RCT, but lower compared to the
placebo group (p = 0.029 and p = 0.001). Glossitis and anal
fissures occurred with a frequency of 3.9 and 1.5%. For details
see Table 3.
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Adverse Events and Discontinuations
The incidence of adverse events was low in the two RCTs
(1.1% for the treatment study and 1.4% for the prevention
FIGURE 2 | Time to resolution of diarrhea (defined as ≥3 stools per day or
liquid or semiliquid stools) in the randomized-controlled treatment trial, shown
as Kaplan-Meier curve [log-rank test p < 0.0001 for SF68 vs. placebo; hazard
ratio 0.7363 (confidence interval 0.6491-0.8353)].
study). Reported events were gastric complaints, abdominal
pain, vomiting and pruritus for the treatment study, and
nausea, abdominal pain, vomiting, pruritis and bloating for
the prevention trial. Adverse events were not more frequently
observed in the SF68 arm compared to controls (Table 4). The
rates of adverse events were higher in the open-label studies (4.7
and 7.4%, respectively). However, only 6.3 and 13.4% of these
adverse events were considered to be SF68-related.
For the treatment RCT, early discontinuation of treatment was
observed in 112 patients in the placebo group (19.6%) and in 119
patients in the SF68 arm (21.1%, n.s.). Treatment discontinuation
due to early cure wasmore frequent in SF68-treated patients (16.8
vs. 13.3%). However, this did not reach statistical significance
(p =0.099). Discontinuation due to intolerability was not
significantly more often in one or the other group (0.4 vs.
1.1%, n.s., Figure 1). Treatment discontinuation for tolerability
reasons in the open-label treatment study was similar as in the
SF68 arm of the controlled study (0.3 vs. 0.4%, n.s.). For the
prevention RCT, early discontinuation of prevention was seen
in 38 patients in the placebo group (5.4%) and in 36 patients in
the SF68 arm (5.2%, n.s.). Discontinuation due to intolerability
was more frequent in the placebo group (0.7 vs. 0.1%).
However, this difference did not reach statistical significance
(p = 0.103). Treatment discontinuation for tolerability reasons
FIGURE 3 | Time to resolution of secondary endpoints in the randomized-controlled treatment trial. (A) ≥3 stools [log-rank test p < 0.001 for SF68 vs. placebo;
hazard ratio 0.8348 (confidence interval 0.7380–0.9443)], (B) liquid or semiliquid stools [log-rank test p < 0.001 for SF68 vs. placebo, hazard ratio 0.8200
(0.7247–0.9277)], (C) mucus on stool [log-rank test p = 0.019 for SF68 vs. placebo, hazard ratio 0.8073 (0.6553–0.9946)], and (D) abdominal pain [log-rank test
p = 0.011 for SF68 vs. placebo, hazard ratio 0.8536 (0.7358–0.9904)].
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TABLE 2 | Baseline demographics and disease characteristics for the prevention studies.
Randomized Open-label
Placebo SF68 total
Gender Male 395 (56.4) 398 (57.1) 793 (56.8) 2,323 (49.8)
Female 305 (43.6) 299 (42.9) 604 (43.2) 2,342 (50.2)
Age <14 years 59 (8.4) 61 (8.8) 120 (8.6) 588 (12.6)
14–20 years 29 (4.1) 19 (2.7) 48 (3.4) 415 (8.9)
21–40 years 99 (14.1) 104 (14.9) 203 (14.5) 1,437 (30.8)
41–60 years 142 (20.3) 166 (23.8) 308 (20.2) 1,255 (26.9)
61–70 years 141 (20.1) 115 (16.5) 256 (18.3) 555 (11.9)
>70 years 230 (32.9) 232 (33.3) 462 (33.1) 415 (8.9)
Treatment setting Hospital 636 (90.9) 634 (91.0) 1,270 (90.9) -
Outpatient 64 (9.1) 63 (9.0) 127 (9.1) 4,665 (100.0)
Type of infection Respiratory 431 (61.6) 421 (60.4) 852 (61.0) 2,558 (54.8)
Urological 122 (17.4) 127 (18.2) 249 (17.8) 1,189 (25.5)
Other 147 (21.0) 149 (21.4) 296 (21.2) 918 (19.7)
Antibiotics Cephalosporin 255 (36.4) 239 (34.3) 494 (35.4) 1,045 (22.4)
Ampi- or amoxicillin 183 (26.1) 182 (26.1) 365 (26.1) 1,227 (26.3)
Aminoglycoside 76 (10.9) 82 (11.8) 158 (11.3) 359 (7.7)
Cotrimoxazole 42 (6.0) 53 (7.6) 95 (6.8) 611 (13.1)
Penicillin 44 (6.3) 31 (4.4) 75 (5.4) 313 (6.7)
Erythromycin 28 (4.0) 27 (3.9) 55 (3.9) 438 (9.4)
Clindomyin/Lincomycin 10 (1.4) 5 (0.7) 15 (1.1) 229 (4.9)
Other 62 (8.9) 78 (11.2) 140 (10.0) 443 (9.5)
Dosing route Parenteral 480 (68.6) 470 (67.4) 950 (68.0) 1,320 (28.3)
Oral 220 (31.4) 227 (32.6) 447 (32.0) 3,345 (71.7)
Early discontinuation Unrelated 33 (4.7) 35 (5.0) 68 (4.9) 279 (6.0)
Tolerability 5 (0.7) 1 (0.1) 6 (0.4) 126 (2.5)
Data are shown as number of patients and % of group in parentheses.
was more frequently observed in the open-label prevention
study (2.5%).
DISCUSSION
This was an analysis of two RCTs evaluating efficacy and
safety of Enterococcus faecium SF68 in the treatment of acute
diarrhea and prevention of antibiotic-associated diarrhea, and
their corresponding open-label studies. Both RCTs were positive
studies for the primary endpoint of a decrease in diarrhea
duration and a reduction in occurrence of new diarrhea cases,
respectively. SF68 was safe and well-tolerated.
With a total number of 6,236 patients included in the
treatment trials and 5,737 subjects in the prevention studies, this
represents by far the largest data set on SF68, actually accounting
for more than half of all patients ever included in clinical trials
with SF68. To the best of our knowledge, it also represents the
largest dataset ever reported for any probiotic in the treatment or
prevention of acute diarrhea (11). While these data were reported
in abstract form in 1986 (19), it remains unclear why these data
have not been reported as full article in the past. Given the
fact that these are the largest trials with SF68 (and probiotics)
in terms of treatment and prevention of acute diarrhea, and
considering the possible impact of these data on clinical practice,
we think it is our duty as caregivers to report these findings.
However, our studies have one clear and major limitation: all
trials were performed in Italy in the 1980s. So, (i) there was no
institutional review board established at the leading study center
at that time (University of Milan) as by then a legally binding
obligation to obtain ethical committee approval had not existed
yet; (ii) European GCP guidelines had not been published, (iii)
apparently no registration on clinicaltrials.gov was done; and (iv)
raw data was not accessible anymore despite intensive efforts
supported by the company holding marketing authorization.
More than 30 years after completion of the studies, they probably
no longer exist as the obligation to preserve records has been
time-barred in the meantime. Nonetheless, the studies adhered
to all rules and regulations applicable in Italy at that time, the
manuscript is based on a thorough study report prepared by
Gipharmex, which was submitted to regulatory authorities in
several countries, and independent statistical re-analyses were
performed where applicable. For full transparency, the study
report can be found in Supplementary Datasheet 1.
Considering all these limitations, a seven-day course of
Enterococcus faecium SF68 was efficacious in the treatment of
acute diarrhea. The rate of patients with ongoing diarrhea for
three or more days was significantly reduced from 59.2 to 50.2%,
and median duration of diarrhea decreased from 4 to 3 days. The
Frontiers in Medicine | www.frontiersin.org 6 June 2020 | Volume 7 | Article 276
Greuter et al. Enterococcus faecium SF68 in the Treatment and Prevention of Diarrhea
results from the open-label study are in line with these findings.
The total number of patients (n = 6,236) and the placebo-
controlled, double-blind study design strengthen the so far
limited evidence for SF68‘s use in the treatment of acute diarrhea
(9). SF68 probably acts by restoring the protective function
carried out by intestinal flora against pathogens. In clinical
practice, shorter disease duration might have the following
considerable impact: (i) less unnecessary treatment escalations
(such as antibiotics for not improving symptoms); (ii) shorter
absence from work and school; (iii) and probably lower health-
care costs due to shorter hospitalizations. However, this has to
be proven and our findings cannot be extrapolated to acute
diarrhea in general, since bacterial infections with Salmonella as
TABLE 3 | Primary and secondary outcomes for the prevention studies in those
patients having completed the 7-day treatment course (per-protocol analysis).
Randomized Open-label
Placebo SF68 P-value
Total n 662 661 4,340
Incidence diarrhea 107 (16.2) 57 (8.6) <0.001 499 (11.5)
Severity grading Light 66 (61.7) 44 (77.2) n.s. 410 (82.2)
Moderate 38 (35.5) 13 (22.8) 79 (15.8)
Severe 3 (2.8) 0 (0.0) 10 (2.0)
Time to occurrence,
days
1 13 (12.1) 7 (12.3) n.s. 65 (13.0)
2 43 (39.3) 19 (33.3) 179 (35.9)
3 26 (24.3) 15 (26.3) 157 (31.5)
4 16 (15.0) 11 (19.3) 60 (12.0)
>4 10 (9.3) 5 (8.8) 38 (7.6)
Duration, days 1 15 (14.0) 18 (31.6.) 0.008* 109 (21.8)
2 38 (35.5) 17 (29.8) 224 (44.9)
>2 54 (50.5) 22 (38.6) 166 (33.3)
Complications Glossitis 31 (4.7) 16 (2.4) 0.026 182 (3.9)
Anal fissures 16 (2.4) 8 (1.2) n.s. 70 (1.5)
Data are number of patients and % of group in parentheses.
*1 day vs. more than 1 day.
well as severely ill patients were excluded. At least in the latter,
other treatment modalities appear to be more adequate than
restoration of intestinal flora, although probiotics may have an
add-on effect.
The prevention studies allowed including patients with a wide
spectrum of types and doses of antibiotics. This can be seen as a
limitation, but also as a benefit of the prevention studies. It is a
limitation because the resulting cohorts are heterogenous, which
makes crisp interpretation of the data more difficult. On the other
hand, this is beneficial because it results in applicability of the
findings to a wide spectrum of antibiotic treatments.
Enterococcus faecium SF68 prevented development of
antibiotic-associated diarrhea. Significantly fewer patients
reported diarrhea under antibiotic treatment when they received
prevention with the probiotic drug (8.6%) compared to placebo
(16.2%). The findings of the open-label study are accordant.
The placebo rate of 16.2% goes in line with previous studies and
meta-analyses showing occurrence of diarrhea with antibiotic
treatment in about 20% (21). So, antibiotic-associated diarrhea
is a problem and can be found in a non-negligible proportion of
patients. The relative reduction of antibiotic-associated diarrhea
by almost 50% (with an estimated number needed to treat of
13) is in accordance with a recent Cochrane review showing
a decrease from 19 to 8% with a mixed group of probiotic
treatments (21). For Enterococcus faecium SF68, our trial
presents, by far, the largest study demonstrating its efficacy in the
prevention of antibiotic-associated diarrhea. Of note, probiotic
preventive treatment has its merits even in those patients
developing diarrhea, since diarrhea appears to be significantly
shorter compared to what is seen in placebo-treated patients.
Since no major advances in regard to antibiotic treatment have
been made in the last two decades, our data are of considerable
value despite the fact that the trial was conducted back in
the 1980s.
Enterococcus faecium SF68 was safe and well-tolerated.
Assessment of overall tolerability showed that adverse events are
very infrequent. In fact, most of the reported adverse events
TABLE 4 | Occurrence of adverse events (AEs) among all four studies.
Treatment studies Prevention studies
Double-blind Open Double-blind Open
placebo SF68 SF68 placebo SF68 SF68
Overall incidence 8/570 (1.4%) 6/564 (1.1%) 238/5,093 (4.7%) 14/700 (2.0%) 10/697 (1.4%) 344/4,665 (7.4%)
Nausea - - 63 (1.2%) 2 2 71 (1.5%)
Gastric complaint 1 3 45 (0.9%) 3 - 75 (1.6%)
Headache 1 - 41 (0.8%) - - 43 (0.9%)
Abdominal pain 2 1 38 (0.7%) 2 1 58 (1.2%)
Vomiting 1 1 34 (0.7%) 3 1 33 (0.7%)
Exanthema or pruritus 2 1 15 (0.3%) 1 2 30 (0.6%)
Constipation 1 - 2 (<0.1%) - - -
Meteorism - - - 2 4 34 (0.7%)
Joint pain - - - 1 - -
Data are shown as number of patients and percent of group in parentheses.
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represent typical symptoms of acute enteritis or known side-
effects of antibiotic treatment. So, even fewer side-effects were
actually related directly to the SF68 treatment. Rate of adverse
events was not higher compared to placebo.
In conclusion, the probiotic Enterococcus faecium SF68 is
effective in the treatment of acute diarrhea and prevention of
antibiotic-associated diarrhea. SF68 is generally well-tolerated
and shows an excellent safety profile. Whether these conclusions
also apply to other strains of Enterococcus faecium remains to
be investigated.
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